Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lyumjev in Inreda bihormonal artificial pancreas for type 1 diabetes
NCT05508061Completed
- Sponsor
- Inreda Diabetic
- Start
- Oct 2022
- Primary completion
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of insulin lispro in type 1 diabetes mellitus (T1D), sponsored by Inreda Diabetic. Primary endpoint: Time Above Range (>10.0 mmol/l) at 25 days. Started Oct 2022; status: completed.
02
Drugs
insulin lispro
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05508061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05508061.